Outcomes After Clot Removal or Medicine Alone for Blocked Smaller Brain Arteries in Stroke
Observes adults with stroke from a blocked branch artery, treated by clot removal or medicine.
Plain-language title generated from the registry record
Registry title: FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
Key facts
- Where
- Charleston, Englewood, Knoxville, Lexington, Memphis, New Haven, and York, United StatesSee the 7 sites
Where in United States
- Medical University of South Carolina (MUSC)Charleston, United StatesTaking people
- Swedish Medical CenterEnglewood, United StatesTaking people
- Fort Sanders Regional Medical CenterKnoxville, United StatesTaking people
- University of KentuckyLexington, United StatesTaking people
- Semmes MurpheyMemphis, United StatesTaking people
- Yale New Haven HospitalNew Haven, United StatesTaking people
- Wellspan York HospitalYork, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Penumbra Inc.
- Trial code
- NCT07749170
- Record updated
- 29 October 2026
- Original description
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical thrombectomy (EVT). Additionally, this study aims to observe characteristics and outcomes of participants treated with medical management (MM) alone and those who receive EVT + MM per current medical practice.Read full original descriptionShow less
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical thrombectomy (EVT). Additionally, this study aims to observe characteristics and outcomes of participants treated with medical management (MM) alone and those who receive EVT + MM per current medical practice.
Inclusion: Participant age ≥ 18; Participant experiencing acute ischemic stroke due to a confirmed primary M2 occlusion in the vertical segment or post-bifurcation in the non-dominant or co-dominant branch of the horizontal segment; NIHSS ≥5 or NIHSS 3-4 with disabling symptoms; Pre-stroke mRS 0-1; For participants undergoing thrombectomy: Planned first-line treatment with Penumbra System reperfusion catheters; Informed consent obtained per Institutional Review Board/Ethics Committee requirements.
Exclusion: Currently participating in an investigational (drug, device, etc.) clinical trial that will influence the endovascular procedure or acute treatment. Participants in secondary prevention, observational, natural history and/or epidemiological studies are eligible; Current hospitalization at time of stroke onset and/or any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days; Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study; Any stenosis or occlusion in the ICA origin requiring treatment during the procedure or within the 90-day follow-up period; Known multiple occlusions; Secondary M2 occlusion; Known or high suspicion of underlying ICAD as the cause of the M2 occlusion.